9 enero 2015
Locally advanced rectal cancer patients who receive preoperative radiation therapy with either irinotecan plus capecitabine or oxaliplatin plus capecitabine have a four-year overall survival rate of 85 percent and 75 percent, respectively, according to a study.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/PuqKF997GQc/150109142517.htm
